Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Recursion Pharmaceuticals Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.82, while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PDBC | RXRX | |
|---|---|---|
52-Week High | $18.91 | $6.79 |
52-Week Low | $12.90 | $2.84 |
Market Cap | — | $1.63B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.65, up 2.32% today, reflecting strong commodity momentum. The technical outlook is bullish with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent news highlights institutional accumulation, such as Geneos Wealth Management increasing its stake by 150.6% in Q1 2026 (Defense World, 2026-07-19). The fund has delivered significant returns, up 37% since March 2024, driven by energy price surges and supply disruptions.
The outlook for PDBC remains positive as a diversified commodities play and inflation hedge, but risks include commodity price volatility and the fund's structural costs. Momentum may weaken if oil prices retreat, as noted in a recent downgrade to hold (Seeking Alpha, 2026-06-11). Investors should weigh the fund's tax advantages against roll costs and cyclical commodity exposure.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
